Clinic Roundup

 Soligenix Inc., of Princeton, N.J., enrolled and treated all patients in a Phase I trial of SGX203 for pediatric Crohn's disease. The goal of the 24-subject study was to characterize the drug's pharmacokinetic and pharmacodynamic profile of the formulation.